68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of the extent of the disease in patients with malignant endocrine tumors: our experience (preliminary results) Abstract #115

Introduction: In neuroendocrine tumors (NETs), the workup is often difficult not only to visualize but also to co-localize the lesions anatomically. Liver and bones are one of the most frequent sites of metastases in patients with endocrine tumors. The Tyr3-octreotate (TATE) somatostatin analogue differs from TOC in that the terminal threonine replaces threoninol. The terminal threonine results in a higher receptor binding (mainly subtype 2) and better internalisation, with the consequence that tumor uptake of the tracer is intense.
Aim(s): To evaluate the diagnostic value of 68Ga-DOTA-TATE PET-CT comparison with 99mTc-HYNIC-TOC SPECT-CT in the assessment of disease extent in patients with malignant neuroendocrine tumors in our institution.
Materials and methods: 68Ga-DOTA-TATE PET-CT and 99mTc-HYNIC-TOC SPECT/CT studies were performed in nine patients. The interval time between of these two studies was 2 – 28 weeks. Conventional scintigraphy was acquired on the hybrid gamma camera SPECT/CT in 2-4 h after intravenous injection of 99mTc-HYNIC-TOC. The injected activity was 550-740 MBq (15-20mCi). The following views were gathered: planar AP, PA and SPECT/CT of the chest and abdomen. PET-CT scans were acquired 45 – 60 min postinjection of 120 – 200 MBq (3.5 – 5.5 mCi) of 68Ga-DOTA-TATE. Data acquisition was performed with a 15-cm axial field of view (FOV) and 55-cm transaxial FOV PET-CT scanner. Patients were imaged in 3-dimensional mode with the duration of acquisition 3 - 5 min per bed position in emission mode.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Norbert Szalus

To read results and conclusion, please login ...

Further abstracts you may be interested in

#867 Mixed Adenoneuroendocrine Carcinoma (MANECs): A Rare and Challenging Subgroup of Neuroendocrine Neoplasia
Introduction: Mixed Adenoneuroendocrine Carcinomas (MANECs) are rare entities in which at least 30% of neoplastic cells are neuroendocrine in nature (WHO 2010 classification). They result either from two independent lesions that merge together or are unique lesions with different cell populations intermingled.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Conor Mosli Lynch
#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#2764 Cystic Pancreatic Neuroendocrine Tumors. Can We Diagnose Them Preoperatively?
Introduction: Pancreatic neueroendocrine tumors rarely undergo cystic changes but they are often misdiagnosed as pancreatic mucinous cystadenoma, mucinous cystadenocarcinoma, serous cystadenoma, and solid and cystic papillary tumors, or pseudocyst.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#777 Laparoscopic Surgery of Functioning Neuroendocrine Tumors of Pancreas
Introduction: Laparoscopic surgery is a feasible technique for benign pancreatic pathologies and has been increasingly reported for neuroendocrine tumors of the pancreas.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Viktor Shkarban